This report on global prostate cancer treatment market studies various drugs used for treatment of prostate cancer along with pipeline analysis of upcoming potential drugs.
According to National Cancer Institute approximately 12.9% of the men will be diagnosed with prostate cancer at some point during their lifetime. Prostate cancer can be diagnosed before the symptoms start by testing the prostate-specific antigen (PSA) in a man’s blood or through the digital rectal exam (DRE). Currently there are a handful of players which are leading the prostate cancer treatment market, but in the future the competition will be more as several blockbuster prostate cancer therapeutic drugs are slated to go off-patent.
The pipeline analysis for prostate cancer treatment market comprises projected market sales of Phase III drugs estimated till 2030. We have estimated sales of very specific molecules based on the type (biological or chemical), sponsor, depicted peak sales by leading market experts and other factors. Few prominent phase III drugs are ProstVac, Tasquinimod Active, ARN-509, ODM-201 and Yervoy etc.
The geographic segmentation of the global prostate cancer treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2023 to 2030 are provided in terms of US$ Mn along with the respective CAGRs for the period 2023 to 2030, considering 2021 as the base year.
The American Cancer Society (ACS) estimates that more than 12 million new cases of cancer are diagnosed worldwide each year. Around 99% of the cases for Prostate cancer is most commonly seen after the age of 50 years. Based on the treatment type, the Prostate cancer treatment market is segmented into:
According to market experts, biological therapy is the first line of treatment in order to reduce androgens in the body (Testosterone, Dihydrotestosterone) as they stimulate the growth of the prostate cancer cells. However, the drug-related side effects are high, so patients are opting for chemotherapy where drugs such as docetaxel, cabazitaxel, mitoxantrone, and estramustine are prescribed for the treatment of prostate cancer. Chemotherapy is a treatment of choice for patients who have become resistant to Biological therapy and Prostate cancer has spread outside the Prostate gland and metastasized in distant organs.
In the base year 2021, biological therapy accounted for the major market share in the treatment followed by Chemotherapy. During the forecast period 2023-2030, targeted Biological therapy is expected to project significant growth due to promising pipeline. The key factors assisting the segment growth were with enhanced reimbursement policies have increased the expenditure for the treatment in developed markets, rise in aging population coupled with growing public awareness, and technological advancement in the drug development with promising pipeline products for the treatment of Prostate cancer.
In the base year 2021, North America held the revenue share majorly due to factors such as the rising prevalence of prostate cancer, increase in the number of prescribed pharmaceuticals products, presence of key manufacturers, the existence of a well-established research and development infrastructure for biopharmaceutical and life science industries. Additionally, and high patient awareness of the disease has led to the early diagnosis and treatment for prostate cancer. It is anticipated that Asia Pacific will be the fastest growing market throughout the forecast period 2023-2030 primarily due to factors such as the growing prevalence of prostate cancer, growing economic condition, growing investments in R&D and increasing treatment awareness. The proactive government policies in the developing nations of the South Asian countries have attracted foreign direct investment to expand the pharmaceutical and life science industries. Furthermore, increasing disposable income is making it possible for the middle-income groups to avail advanced healthcare facilities is another factor that driving the prostate cancer treatment market growth in Asia Pacific region.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Prostate Cancer Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Treatment
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
